UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

19 New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Read More Share:

Mar

12 Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Read More Share:

Mar

07 Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Read More Share:

Mar

07 BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Read More Share:

Mar

07 BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Read More Share:

Mar

05 Voices on Value: Prioritizing Patients Now and Into the Future

Read More Share:

Mar

04 CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Read More Share:

Feb

27 On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Read More Share:

Feb

26 Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

Read More Share:

Feb

25 Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

Read More Share:

Categories

Archives

Mar

19

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Mar

12

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Mar

07

Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Mar

05

Voices on Value: Prioritizing Patients Now and Into the Future

Mar

04

CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Feb

27

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Feb

26

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

Feb

25

Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Mar

19

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Mar

12

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Mar

07

Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Mar

05

Voices on Value: Prioritizing Patients Now and Into the Future

Mar

04

CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Feb

27

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Feb

26

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

Feb

25

Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact